1
|
Barywani SB, Östgärd Thunström E, Mandalenakis Z, Hansson PO. Body iron stores had no impact on coronary heart disease outcomes: a middle-aged male cohort from the general population with 21-year follow-up. Open Heart 2022; 9:openhrt-2021-001928. [PMID: 35410912 PMCID: PMC9003602 DOI: 10.1136/openhrt-2021-001928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Accepted: 03/22/2022] [Indexed: 11/03/2022] Open
Abstract
BackgroundBody iron stores (BISs) have been proposed to be related to the development of cardiovascular diseases. However, results from epidemiological studies are conflicting. Knowledge on the long-term impact of BIS on cardiovascular outcomes in the general population is lacking.PurposeThe aim of this study was to explore the relationship between BIS and coronary heart disease (CHD) including death due to CHD.MethodsThis investigation is part of ‘The Study of Men Born in 1943’, a longitudinal prospective study of men living in the city of Gothenburg, Sweden. This random population sample was examined in 1993 (all at 50 years of age at baseline). A medical examination was performed, and questionnaires were used to evaluate lifestyle factors. Biomarkers for iron stores (serum ferritin and serum transferrin receptor) was analysed from frozen blood samples in 2014. All hospital admissions were registered through national registers during the entire follow-up from 1993 to 2014. HRs were estimated by Cox proportional-hazard regression analyses.ResultsDuring the 21 years follow-up period, 120 participants (15.2%) developed CHD and 16 patients (2%) died due to CHD. The all-cause mortality was 15.2% (n=120) including 40 cardiovascular deaths (5.1%). In a multivariable Cox regression analysis, the daily smoking, hypertension and the increased resting heart rate was independent predictors of CHD, while no significant association was found between BIS and risk of CHD.ConclusionsIn a cohort of middle-aged men from the general population with well validated and prospectively collected data, we did not find any association between serum ferritin or serum transferrin receptor as markers of BIS and CHD events after 21 years of follow-up.Trail registration numberNCT03138122.
Collapse
Affiliation(s)
- Salim Bary Barywani
- Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Medicine, Gothemburg, Sweden
- Department of Medicine, Geriatrics and Emergency Medicine/Östra, Sahlgrenska University Hospital, Region VästraGötaland, Medicine, Gothenburg, Sweden
| | - Erik Östgärd Thunström
- Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Medicine, Gothemburg, Sweden
- Department of Medicine, Geriatrics and Emergency Medicine/Östra, Sahlgrenska University Hospital, Region VästraGötaland, Medicine, Gothenburg, Sweden
| | - Zacharias Mandalenakis
- Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Medicine, Gothemburg, Sweden
- Department of Medicine, Geriatrics and Emergency Medicine/Östra, Sahlgrenska University Hospital, Region VästraGötaland, Medicine, Gothenburg, Sweden
| | - Per-Olof Hansson
- Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Medicine, Gothemburg, Sweden
- Department of Medicine, Geriatrics and Emergency Medicine/Östra, Sahlgrenska University Hospital, Region VästraGötaland, Medicine, Gothenburg, Sweden
| |
Collapse
|
2
|
Miramontes-González JP, Usategui-Martín R, Martín-Vallejo J, Ziegler M, de Isla LL, O Connor D, González-Sarmiento R. VAV3 rs7528153 and VAV3-AS1 rs1185222 polymorphisms are associated with an increased risk of developing hypertension. Eur J Intern Med 2020; 80:60-65. [PMID: 32540412 DOI: 10.1016/j.ejim.2020.05.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Revised: 05/05/2020] [Accepted: 05/11/2020] [Indexed: 01/04/2023]
Abstract
The aetiology of essential hypertension is complex and involves both environmental and genetic factors. Approximately 30% of the inter-individual variability in blood pressure is genetically determined. It has been shown that numerous vasoconstrictors stimulate RhoA in local populations of vascular SMCs that, in turn, promote localised constriction of arterial blood vessels and elevations in blood pressure. The VAV3 gene encodes for VAV3 protein, a Rho GEF factor. VAV3-AS1 gene, a lncRNA, may regulate VAV3 expression. We performed an observational prospective case-control study, including patients attending in the Vascular Risk Unit from the University Hospital Salamanca for 6 months. A replication study was performed with data from The Kaiser Permanent database of the University of California. The results suggest that T allele of the VAV3 rs7528153 and G allele of the VAV3-AS1 rs11185222 polymorphisms are associated with an increased risk of developing hypertension. We hypothesise that these polymorphisms could modify blood pressure, likely through a modification in the Rho/Rac pathway. Our results suggest that those polymorphisms could be useful genetic markers of susceptibility to suffering hypertension.
Collapse
Affiliation(s)
- José Pablo Miramontes-González
- Department of Internal Medicine, Hospital Universitario de Salamanca, Valladolid, Spain; Molecular Medicine Unit, Department of Medicine, Universidad de Salamanca, Salamanca, Spain; Institute of Biomedical Research of Salamanca (IBSAL), Hospital Universitario de Salamanca-USAL-CSIC and Institute of Molecular and Cellular Biology of Cancer (IBMCC), Universidad de Salamanca-CSIC, Salamanca, Spain; Department of Medicine. University of California at San Diego, La Jolla, California-UCSD, United States.
| | - Ricardo Usategui-Martín
- Molecular Medicine Unit, Department of Medicine, Universidad de Salamanca, Salamanca, Spain; Institute of Biomedical Research of Salamanca (IBSAL), Hospital Universitario de Salamanca-USAL-CSIC and Institute of Molecular and Cellular Biology of Cancer (IBMCC), Universidad de Salamanca-CSIC, Salamanca, Spain
| | - Javier Martín-Vallejo
- Institute of Biomedical Research of Salamanca (IBSAL), Hospital Universitario de Salamanca-USAL-CSIC and Institute of Molecular and Cellular Biology of Cancer (IBMCC), Universidad de Salamanca-CSIC, Salamanca, Spain; Department of Statistics, Universidad de Salamanca, Salamanca, Spain
| | - Michael Ziegler
- Department of Medicine. University of California at San Diego, La Jolla, California-UCSD, United States
| | - Leopoldo López de Isla
- Cardiac Image Unit. Hospital Clínico San Carlos. Madrid. Facultad de Medicina. Universidad Complutense de Madrid, Madrid, Spain
| | - Daniel O Connor
- Department of Medicine. University of California at San Diego, La Jolla, California-UCSD, United States
| | - Rogelio González-Sarmiento
- Molecular Medicine Unit, Department of Medicine, Universidad de Salamanca, Salamanca, Spain; Institute of Biomedical Research of Salamanca (IBSAL), Hospital Universitario de Salamanca-USAL-CSIC and Institute of Molecular and Cellular Biology of Cancer (IBMCC), Universidad de Salamanca-CSIC, Salamanca, Spain.
| |
Collapse
|
3
|
Abstract
Ferritin and increased iron stores first appeared on the list of cardiovascular risk factors more than 30 years ago and their causal role in the pathogenesis of atherosclerosis has been heavily discussed since the early 1990s. It seems that besides traditional factors such as hyperlipoproteinemia, hypertension, diabetes mellitus, obesity, physical inactivity, smoking and family history, high iron stores represent an additional parameter that could modify individual cardiovascular risk. The role of iron in the pathogenesis of atherosclerosis was originally primarily associated with its ability to catalyze the formation of highly reactive free oxygen radicals and the oxidation of atherogenic lipoproteins. Later, it became clear that the mechanism is more complex. Atherosclerosis is a chronic fibroproliferative inflammatory process and iron, through increased oxidation stress as well as directly, can control both native and adaptive immune responses. Within the arterial wall, iron affects all of the cell types that participate in the atherosclerotic process (monocytes/macrophages, endothelial cells, vascular smooth muscle cells and platelets). Most intracellular iron is bound in ferritin, whereas redox-active iron forms labile iron pool. Pro-inflammatory and anti-inflammatory macrophages within arterial plaque differ with regard to the amount of intracellular iron and most probably with regard to their labile iron pool. Yet, the relation between plasma ferritin and intracellular labile iron pool has not been fully clarified. Data from population studies document that the consumption of meat and lack of physical activity contribute to increased iron stores. Patients with hereditary hemochromatosis, despite extreme iron storage, do not show increased manifestation of atherosclerosis probably due to the low expression of hepcidin in macrophages.
Collapse
Affiliation(s)
- P Kraml
- Second Department of Internal Medicine, Third Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic.
| |
Collapse
|
4
|
Molekulargenetische Analyse und klinische Aspekte bei Patienten mit hereditärer Hämochromatose. DER ORTHOPADE 2014; 43:772-9. [DOI: 10.1007/s00132-014-2318-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
5
|
Human heart rate: heritability of resting and stress values in twin pairs, and influence of genetic variation in the adrenergic pathway at a microribonucleic acid (microrna) motif in the 3'-UTR of cytochrome b561 [corrected]. J Am Coll Cardiol 2013; 63:358-68. [PMID: 24140660 DOI: 10.1016/j.jacc.2013.09.025] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2013] [Revised: 08/30/2013] [Accepted: 09/03/2013] [Indexed: 11/21/2022]
Abstract
OBJECTIVES The goal of this study was to understand the role of genetic variation in the catecholamine biosynthetic pathway for control of human heart rate (HR). BACKGROUND Human HR is an integrated cardiovascular trait predictive of morbidity and survival. Because the autonomic pathway exerts rapid control over the heart, we probed the role of heredity in the control of HR, focusing on a component of the autonomic sympathetic pathway already predictive of outflow responses: cytochrome b561 (CYB561), the electron shuttle in catecholamine vesicle membranes for transmitter biosynthesis. METHODS We studied hereditary control of HR with the twin pair design, at rest and during environmental (cold) stress. Single nucleotide polymorphism disruption of a microribonucleic acid (microRNA) recognition motif in the human CYB561 3'-UTR was identified computationally, and its differential effect on gene expression was demonstrated in a transfected luciferase reporter/3'-UTR variant. We exposed stem cell-derived human embryoid bodies to the microRNA mimic or antagomir oligonucleotides, and we observed the effects on contraction rate in proto-hearts. RESULTS Substantial heritability (h(2)) was demonstrated by using twin pair variance components for both basal/resting HR (h(2) 50.9 ± 6.4% of trait variation, p = 2.47 × 10(-10)) and stress-augmented HR (h(2) 55.1 ± 5.9%, p = 8.79 × 10(-13)), and the 2 HR traits shared genetic determination (genetic covariance ρG 0.747 ± 0.058, p = 2.85 × 10(-9)). CYB561 displayed 1 common genetic variant in the transcript region: A+1485G (rs3087776), in the 3'-UTR, 1485 bp downstream of the termination codon, in a conserved region, with the A-allele ancestral in primates. In a twin/sibling sample (n = 576), A+1485G influenced HR, both at rest (p = 0.010) and after environmental stress (p = 0.002), with the minor (A) allele displaying a recessive effect with lower HR. The effect of A+1485G on HR was extended by meta-analysis into 2 additional population samples (total n = 2,579), and the influence remained directionally consistent and significant (p = 0.007). A+1485G disrupted a microRNA (human microribonucleic acid-1294 [hsa-miR-1294]) recognition motif in the 3'-UTR, as demonstrated by a transfected luciferase reporter/human 3'-UTR variant system in 2 different neuronal/neuroendocrine cell types. The microRNA effect was further documented by cotransfection of an hsa-miR-1294 mimic, yielding an exaggerated decline in expression of the A-allele (better match) reporter (p = 4.3 × 10(-5)). Similar findings of differential 3'-UTR allelic susceptibility to hsa-miR-1294 were noted during expression of the full-length human CYB561 messenger ribonucleic acid with its cognate 3'-UTR. Finally, exposure of stem cell-derived human embryoid bodies to hsa-miR-1294 mimic or antagomir oligonucleotides yielded directionally opposite effects on contraction rate in proto-hearts. CONCLUSIONS HR is a substantially heritable trait, with genetic influence by variation in the adrenergic pathway, here shown for messenger ribonucleic acid translational control at the CYB561 step of transmitter formation. The results have implications for potentially modifiable autonomic pathways that influence this risk trait in the population.
Collapse
|
6
|
Lian J, Xu L, Huang Y, Le Y, Jiang D, Yang X, Xu W, Huang X, Dong C, Ye M, Zhou J, Duan S. Meta-analyses of HFE variants in coronary heart disease. Gene 2013; 527:167-73. [PMID: 23792061 DOI: 10.1016/j.gene.2013.06.034] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2013] [Revised: 05/17/2013] [Accepted: 06/03/2013] [Indexed: 11/16/2022]
Abstract
AIM HFE gene variants can cause hereditary hemochromatosis (HH) that often comes along with an increased risk of coronary heart disease (CHD). The goal of our study is to assess the contribution of four HFE gene variants to the risk of CHD. METHODS AND RESULTS We conducted four meta-analyses of the studies examining the association between four HFE gene variants and the risk of CHD. A systematic search was conducted using MEDLINE, EMBASE, Web of Science and China National Knowledge Infrastructure (CNKI), Wanfang Chinese Periodical. RESULTS Meta-analyses showed that HFE rs1799945-G allele was associated with a 6% increased risk of CHD (P=0.02, odds ratio (OR)=1.06, 95% confidence interval (CI)=1.01-1.11). However, no association between the other three HFE gene variants (rs1800562, rs1800730, and rs9366637) and CHD risk was observed by the meta-analyses (all P values>0.05). In addition, the results of our case-control study indicated that rs1800562 and rs1800730 were monomorphic, and that rs1799945 and rs9366637 were not associated with CHD in Han Chinese. CONCLUSIONS Our meta-analysis suggested that a significant association existed between rs1799945 mutation and CHD, although this mutation was rare in Han Chinese.
Collapse
Affiliation(s)
- Jiangfang Lian
- Ningbo Medical Center, Lihuili Hospital, Ningbo University, Ningbo, Zhejiang 315041, China
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Zhang K, Rao F, Miramontes-Gonzalez JP, Hightower CM, Vaught B, Chen Y, Greenwood TA, Schork AJ, Wang L, Mahata M, Stridsberg M, Khandrika S, Biswas N, Fung MM, Waalen J, Middelberg RP, Heath AC, Montgomery GW, Martin NG, Whitfield JB, Baker DG, Schork NJ, Nievergelt CM, O'Connor DT. Neuropeptide Y (NPY): genetic variation in the human promoter alters glucocorticoid signaling, yielding increased NPY secretion and stress responses. J Am Coll Cardiol 2012; 60:1678-89. [PMID: 23021333 DOI: 10.1016/j.jacc.2012.06.042] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2012] [Revised: 06/15/2012] [Accepted: 06/15/2012] [Indexed: 01/09/2023]
Abstract
OBJECTIVES This study sought to understand whether genetic variation at the Neuropeptide Y (NPY) locus governs secretion and stress responses in vivo as well as NPY gene expression in sympathochromaffin cells. BACKGROUND The NPY is a potent pressor peptide co-released with catecholamines during stress by sympathetic axons. Genome-wide linkage on NPY secretion identified a LOD (logarithm of the odds ratio) peak spanning the NPY locus on chromosome 7p15. METHODS Our approach began with genomics (linkage and polymorphism determination), extended into NPY genetic control of heritable stress traits in twin pairs, established transcriptional mechanisms in transfected chromaffin cells, and concluded with observations on blood pressure (BP) in the population. RESULTS Systematic polymorphism tabulation at NPY (by re-sequencing across the locus: promoter, 4 exons, exon/intron borders, and untranslated regions; on 2n = 160 chromosomes of diverse biogeographic ancestries) identified 16 variants, of which 5 were common. We then studied healthy twin/sibling pairs (n = 399 individuals), typing 6 polymorphisms spanning the locus. Haplotype and single nucleotide polymorphism analyses indicated that proximal promoter variant ∇-880Δ (2-bp TG/-, Ins/Del, rs3037354) minor/Δ allele was associated with several heritable (h(2)) stress traits: higher NPY secretion (h(2) = 73 ± 4%) as well as greater BP response to environmental (cold) stress, and higher basal systemic vascular resistance. Association of ∇-880Δ and plasma NPY was replicated in an independent sample of 361 healthy young men, with consistent allelic effects; genetic variation at NPY also associated with plasma NPY in another independent series of 2,212 individuals derived from Australia twin pairs. Effects of allele -880Δ to increase NPY expression were directionally coordinate in vivo (on human traits) and in cells (transfected NPY promoter/luciferase reporter activity). Promoter -880Δ interrupts a novel glucocorticoid response element motif, an effect confirmed in chromaffin cells by site-directed mutagenesis on the transfected promoter, with differential glucocorticoid stimulation of the motif as well as alterations in electrophoretic mobility shifts. The same -880Δ allele also conferred risk for hypertension and accounted for approximately 4.5/approximately 2.1 mm Hg systolic BP/diastolic BP in a population sample from BP extremes. CONCLUSIONS We conclude that common genetic variation at the NPY locus, especially in proximal promoter ∇-880Δ, disrupts glucocorticoid signaling to influence NPY transcription and secretion, raising systemic vascular resistance and early heritable responses to environmental stress, eventuating in elevated resting BP in the population. The results point to new molecular strategies for probing autonomic control of the human circulation and ultimately susceptibility to and pathogenesis of cardiovascular and neuropsychiatric disease states.
Collapse
Affiliation(s)
- Kuixing Zhang
- Department of Medicine and Institute for Genomic Medicine, University of California at San Diego, San Diego, California, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Elmberg M, Hultcrantz R, Simard JF, Stål P, Pehrsson K, Askling J. Risk of ischaemic heart disease and cardiomyopathy in patients with haemochromatosis and in their first-degree relatives: a nationwide, population-based study. J Intern Med 2012; 272:45-54. [PMID: 22026548 DOI: 10.1111/j.1365-2796.2011.02475.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND Iron-loaded macrophages increase atherosclerosis formation. Genetic haemochromatosis (GH) is an autosomal recessive disease characterized by iron overload, for example in the myocardium, but the reticuloendothelial system is depleted of iron. In contrast to the elevated risk of cardiomyopathy in GH, the risk of ischaemic heart disease (IHD) may therefore not be increased. Little is known of these risks among heterozygotes also being first-degree relatives (FDRs), thus sharing other factors for phenotypic expression of GH. OBJECTIVE To assess the risks of IHD and cardiomyopathy among haemochromatosis patients and their FDRs. DESIGN Population-based cohort study. SETTING AND SUBJECTS A total of 3531 haemochromatosis patients and 11 794 FDRs were identified using nationwide, population-based health and census registers. Matched (1:10) population controls were randomly selected. Individuals with a record of IHD and cardiomyopathy during 1997-2005 were identified through linkage with the National Patient Register. Relative risks were estimated using Cox proportional hazard regression. RESULTS Of the 3531 patients, 259 were diagnosed with IHD compared with 3077 of the 37 369 controls [hazard ratio (HR) = 1.17; 95% CI, 1.03-1.33]. Based on 30 patients versus 115 controls, the HR for cardiomyopathy was 3.21 (95% CI, 2.15-4.81). Of 11 794 FDRs of haemochromatosis patients, 582 were registered with IHD compared with 6197 among FDRs of controls (HR = 1.05; 95% CI, 0.97-1.15). Based on 28 FDRs of patients versus 291 FDRs of controls registered with cardiomyopathy, the HR for cardiomyopathy was 1.06 (95% CI, 0.72-1.56). CONCLUSIONS In patients with haemochromatosis, the increased risk of cardiomyopathy is much more pronounced than that of IHD, which is barely elevated. FDRs of haemochromatosis patients are not at increased risk of cardiomyopathy or IHD.
Collapse
Affiliation(s)
- M Elmberg
- Division of Gastroenterology and Hepatology, Karolinska University Hospital Clinical, Stockholm, Sweden.
| | | | | | | | | | | |
Collapse
|
9
|
Shi Y, Zhou L, Huang LH, Lian YT, Zhang XM, Guo H, Wu TC, Cheng LX, He MA. Plasma ferritin levels, genetic variations in HFE gene, and coronary heart disease in Chinese: a case-control study. Atherosclerosis 2011; 218:386-90. [PMID: 21696736 DOI: 10.1016/j.atherosclerosis.2011.05.040] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2011] [Revised: 05/03/2011] [Accepted: 05/24/2011] [Indexed: 10/18/2022]
Abstract
BACKGROUND The association between body iron stores and coronary heart disease (CHD) was inconsistent. We sought to explore this association in Chinese Han population and further examine the association of the variations in hemochromatosis (HFE) gene and CHD risk. METHODS We conducted a case-control study including 1334 CHD patients and 1334 age- and sex-frequency matched controls. The plasma ferritin levels were measured by enzyme linked immunosorbent assay. Genotypes of the tagging single nucleotide polymorphisms (tagSNPs) were determined by TaqMan SNP allelic discrimination. RESULTS The plasma ferritin levels in CHD cases (197.9μg/L [2.7-932.9μg/L]) were higher than those in controls (179.9μg/L [21.1-878.2μg/L]; P=0.028). The odds ratios (ORs) across the tertiles of plasma ferritin levels were 1.0 (reference), 0.93 (0.76-1.13), and 1.23 (1.02-1.48; P for trend=0.028). Adjustment for the traditional risk factors attenuated the associations to null (P for trend=0.22). Compared with the TT genotype of tagSNP rs9366637, subjects with C allele had higher risk of CHD (OR=1.35 for TC and 1.76 for CC; P=0.001 and <0.001 respectively). After adjustment for the conventional risk factors the results remained unchanged. We did not find significantly different plasma ferritin levels among different genotypes of rs9366637 (P=0.52). CONCLUSIONS The plasma ferritin levels were not significantly associated with CHD risk. However, the SNP rs9366637 in HFE gene was associated with higher CHD risk in Chinese Han population. The underlie mechanism remained to be elucidated in further studies.
Collapse
Affiliation(s)
- Y Shi
- Department of Cardiology, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Human dopamine β-hydroxylase promoter variant alters transcription in chromaffin cells, enzyme secretion, and blood pressure. Am J Hypertens 2011; 24:24-32. [PMID: 20814407 DOI: 10.1038/ajh.2010.186] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Dopamine β-hydroxylase (DBH) plays an indispensable role in catecholamine synthesis by converting dopamine into norepinephrine. Here, we characterized a DBH promoter polymorphism (C-2073T; rs1989787; minor allele frequency ~16%) that influences not only gene transcription but also enzyme secretion and blood pressure (BP) in vivo. METHODS Plasma DBH activity was measured spectrophotometrically. DBH genetic effects on BP were tested in subjects with the most extreme BP values in a large primary care population. Functional effects of promoter variants were studied by site-directed mutagenesis in DBH promoter haplotype/luciferase reporter plasmids transfected into chromaffin cells. Sequence motifs were predicted from position weight matrices, and endogenous transcription factor binding was probed by Chromatin ImmunoPrecipitation (ChIP). RESULTS The T-allele of common promoter variant C-2073T was contained in a promoter haplotype that associated with plasma DBH activity, a trait also predicted by that variant itself. Promoter haplotypes including C-2073T predicted BP in the population, and the effect was also referable to C-2073T itself. Computationally, C-2073 disrupted a predicted match for transcription factor c-FOS. Site-directed mutagenesis at C-2073T altered not only basal promoter activity, but also transactivation by c-FOS, as well as the chromaffin cell secretory stimuli nicotine or pituitary adenylate cyclase-activating polypeptide (PACAP). Endogenous c-FOS bound to the motif in chromatin. CONCLUSIONS These results suggest that DBH promoter variant C-2073T is functional in vivo: this promoter variant seems to initiate a cascade of transcriptional and biochemical changes including augmented DBH secretion, eventuating in elevation of basal BP, and hence cardiovascular risk. The observations suggest new strategies for probing the pathophysiology, risk, and treatment of hypertension.
Collapse
|
11
|
Common functional genetic variants in catecholamine storage vesicle protein promoter motifs interact to trigger systemic hypertension. J Am Coll Cardiol 2010; 55:1463-75. [PMID: 20359597 DOI: 10.1016/j.jacc.2009.11.064] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2009] [Revised: 11/10/2009] [Accepted: 11/24/2009] [Indexed: 12/28/2022]
Abstract
OBJECTIVES The purpose of this study is to understand whether naturally occurring genetic variation in the promoter of chromogranin B (CHGB), a major constituent of catecholamine storage vesicles, is functional and confers risk for cardiovascular disease. BACKGROUND CHGB plays a necessary (catalytic) role in catecholamine storage vesicle biogenesis. Previously, we found that genetic variation at CHGB influenced autonomic function, with association maximal toward the 5' region. METHODS Here we explored transcriptional mechanisms of such effects, characterizing 2 common variants in the proximal promoter, A-296C and A-261T, using transfection/cotransfection, electrophoretic mobility shift assay (EMSA), and chromatin immunoprecipitation (ChIP). We then tested the effects of promoter variation on cardiovascular traits. RESULTS The A-296C disrupted a c-FOS motif, exhibiting differential mobility shifting to chromaffin cell nuclear proteins during EMSA, binding of endogenous c-FOS on ChIP, and differential response to exogenous c-FOS. The A-261T disrupted motifs for SRY and YY1, with similar consequences for EMSA, endogenous factor binding, and responses to exogenous factors. The 2-SNP CHGB promoter haplotypes had a profound (p=3.16E-20) effect on blood pressure (BP) in the European ancestry population, with a rank order of CT<AA<<CA<AT on both systolic blood pressure (SBP) and diastolic blood pressure (DBP), accounting for approximately 2.3% to approximately 3.4% of SBP/DBP variance; the haplotype effects on BP in vivo paralleled those on promoter activity in cella. Site-by-site interactions at A-296C and A-261T yielded highly nonadditive effects on SBP/DBP. The CHGB haplotype effects on BP were also noted in an independent (African ancestry) sample. In normotensive twins, parallel effects were noted for a pre-hypertensive phenotype, BP response to environmental stress. CONCLUSIONS The common CHGB promoter variants A-296C and A-261T, and their consequent haplotypes, alter binding of specific transcription factors to influence gene expression in cella as well as BP in vivo. Such variation contributes substantially to risk for human hypertension. Involvement of the sex-specific factor SRY suggests a novel mechanism for development of sexual dimorphism in BP.
Collapse
|
12
|
Zhang K, Rao F, Rana BK, Gayen JR, Calegari F, King A, Rosa P, Huttner WB, Stridsberg M, Mahata M, Vaingankar S, Mahboubi V, Salem RM, Rodriguez-Flores JL, Fung MM, Smith DW, Schork NJ, Ziegler MG, Taupenot L, Mahata SK, O'Connor DT. Autonomic function in hypertension; role of genetic variation at the catecholamine storage vesicle protein chromogranin B. ACTA ACUST UNITED AC 2010; 2:46-56. [PMID: 20011129 DOI: 10.1161/circgenetics.108.785659] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- Kuixing Zhang
- Department of Medicine and CHGG, UCSD School of Medicine, 9500 GilmanDrive, La Jolla, CA 92093-0838. E-mail: or
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
The effect of dietary iron intake on the development of iron overload among homozygotes for haemochromatosis. Public Health Nutr 2009; 12:1823-9. [DOI: 10.1017/s1368980008004631] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
AbstractObjectiveTo quantify the role of dietary Fe in total body Fe (TBI) accumulation among homozygotes for theHFEgene associated with haemochromatosis.DesignA Monte Carlo model was built to simulate Fe accumulation based on findings from human feeding experiments and national dietary surveys. A hypothetical cohort of 1000 homozygotes with starting age 25 years was used in 39-year simulations. The impact of reducing dietary Fe intake on Fe accumulation was tested.ResultsIn the baseline model without any dietary intervention, by age 64, the percentage of males with TBI > 10 g, >15 g and >20 g was 93·2 %, 49·6 % and 14·7 %, respectively. When the Fe intake of individuals in the cohort was reduced to ≤200 % of the recommended dietary allowance (RDA), the corresponding percentages were 92·0 %, 40·5 % and 10·2 %, respectively. The corresponding figures were 91·0 %, 40·0 % and 9·3 % for Fe defortification and 70·3 %, 21·3 % and 4·1 % when Fe intake was capped at 100 % RDA. Similar trends were seen with sexes combined, although the impact of interventions was less. Sensitivity analysis revealed that the rate of Fe accumulation and the impact of dietary interventions are highly dependent on assumptions concerning Fe absorption rates.ConclusionsVariation in Fe intake as currently observed in the USA contributes to variation in Fe accumulation among homozygotes, when continued over an extended period. Lifelong dietary habits and national fortification policy can affect the rate of Fe accumulation, although the magnitude of the effect varies by gender, the TBI level of interest and factors affecting the Fe absorption rate.
Collapse
|
14
|
Wang L, Rao F, Zhang K, Mahata M, Rodriguez-Flores JL, Fung MM, Waalen J, Cockburn MG, Hamilton BA, Mahata SK, O'Connor DT. Neuropeptide Y1Receptor NPY1R. J Am Coll Cardiol 2009; 54:944-54. [DOI: 10.1016/j.jacc.2009.05.035] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2009] [Revised: 05/13/2009] [Accepted: 05/14/2009] [Indexed: 10/20/2022]
|
15
|
Marx JJ, Kartikasari AE, Georgiou NA. Can Iron Chelators Influence the Progression of Atherosclerosis? Hemoglobin 2009; 32:123-34. [DOI: 10.1080/03630260701726871] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
16
|
Chen Y, Rao F, Rodriguez-Flores JL, Mahata M, Fung MM, Stridsberg M, Vaingankar SM, Wen G, Salem RM, Das M, Cockburn MG, Schork NJ, Ziegler MG, Hamilton BA, Mahata SK, Taupenot L, O'Connor DT. Naturally occurring human genetic variation in the 3'-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion. J Am Coll Cardiol 2008; 52:1468-81. [PMID: 19017515 DOI: 10.1016/j.jacc.2008.07.047] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/16/2008] [Revised: 07/14/2008] [Accepted: 07/17/2008] [Indexed: 02/07/2023]
Abstract
OBJECTIVES We aimed to determine whether the common variation at the chromogranin A (CHGA) locus increases susceptibility to hypertension. BACKGROUND CHGA regulates catecholamine storage and release. Previously we systematically identified genetic variants across CHGA. METHODS We carried out dense genotyping across the CHGA locus in >1,000 individuals with the most extreme blood pressures (BPs) in the population, as well as twin pairs with autonomic phenotypes. We also characterized the function of a trait-associated 3'-untranslated region (3'-UTR) variant with transfected CHGA 3'-UTR/luciferase reporter plasmids. RESULTS CHGA was overexpressed in patients with hypertension, especially hypertensive men, and CHGA predicted catecholamines. In individuals with extreme BPs, CHGA genetic variants predicted BP, especially in men, with a peak association occurring in the 3'-UTR at C+87T, accounting for up to approximately 12/ approximately 9 mm Hg. The C+87T genotype predicted CHGA secretion in vivo, with the +87T allele (associated with lower BP) also diminishing plasma CHGA by approximately 10%. The C+87T 3'-UTR variant also predicted the BP response to environmental (cold) stress; the same allele (+87T) that diminished basal BP in the population also decreased the systolic BP response to stress by approximately 12 mm Hg, and the response was smaller in women (by approximately 6 mm Hg). In a chromaffin cell-transfected CHGA 3'-UTR/luciferase reporter plasmid, the +87T allele associated with lower BP also decreased reporter expression by approximately 30%. In cultured chromaffin cells, reducing endogenous CHGA expression by small interfering ribonucleic acid caused approximately two-thirds depletion of catecholamine storage vesicles. CONCLUSIONS Common variant C+87T in the CHGA 3'-UTR is a functional polymorphism causally associated with hypertension especially in men of the population, and we propose steps ("intermediate phenotypes") whereby in a sex-dependent fashion this genetic variant influences the ultimate disease trait. These observations suggest new molecular strategies to probe the pathophysiology, risk, and rational treatment of hypertension.
Collapse
Affiliation(s)
- Yuqing Chen
- Department of Medicine, Center for Human Genetics and Genomics, University of California at San Diego, San Diego, California 92093, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
van der A DL, Rovers MM, Grobbee DE, Marx JJ, Waalen J, Ellervik C, Nordestgaard BG, Olynyk JK, Mills PR, Shepherd J, Grandchamp B, Boer JM, Caruso C, Arca M, Meyer BJ, van der Schouw YT. Mutations in the HFE Gene and Cardiovascular Disease Risk. ACTA ACUST UNITED AC 2008; 1:43-50. [DOI: 10.1161/circgenetics.108.773176] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Whether mutations in the hemochromatosis (HFE) gene increase cardiovascular disease risk is still undetermined. The main reason is the low frequency of the mutations, in particular of the compound C282Y/H63D genotype. We combined the data of 11 observational studies for an individual patient data meta-analysis.
Methods and Results—
Individual patient data were obtained from published as well as unpublished studies that had information available on the C282Y mutation as well as the H63D mutation in relation to coronary heart disease risk. Individual records were provided on each of the 53 880 participants in 11 studies. In total, 10 541 patients with coronary events were documented, of whom 5724 had an acute myocardial infarction. The crude and adjusted association between HFE genotypes and coronary events was examined by logistic regression analysis. We explored potential effect modification of the association between traditional cardiovascular risk factors and coronary events by HFE genotypes. After full adjustment, the odds ratio for coronary heart disease was 1.12 (95% CI, 0.92 to 1.37) for subjects with the compound heterozygous (C282Y/H63D) genotype relative to those with the wild-type/wild-type genotype. The odds ratios for C282Y/C282Y, C282Y/wild-type, H63D/H63D, and H63D/wild-type were 0.78 (95% CI, 0.49 to 1.26), 0.98 (95% CI, 0.90 to 1.07), 1.16 (95% CI, 0.97 to 1.38), and 1.07 (95% CI, 1.00 to 1.14), respectively. There was no evidence for effect modification.
Conclusions—
The results of this large individual patient data meta-analysis do not support the view that HFE gene mutations are associated with an increased risk of coronary heart disease or acute myocardial infarction.
Collapse
Affiliation(s)
- Daphne L. van der A
- From the National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.L.v.d.A., J.M.A.B.); Julius Center for Health Sciences and Primary Care (D.L.v.d.A., M.M.R., D.E.G., Y.T.v.d.S.) and Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation (J.J.M.M.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif (J.W.); Department of Clinical
| | - Maroeska M. Rovers
- From the National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.L.v.d.A., J.M.A.B.); Julius Center for Health Sciences and Primary Care (D.L.v.d.A., M.M.R., D.E.G., Y.T.v.d.S.) and Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation (J.J.M.M.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif (J.W.); Department of Clinical
| | - Diederick E. Grobbee
- From the National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.L.v.d.A., J.M.A.B.); Julius Center for Health Sciences and Primary Care (D.L.v.d.A., M.M.R., D.E.G., Y.T.v.d.S.) and Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation (J.J.M.M.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif (J.W.); Department of Clinical
| | - Joannes J.M. Marx
- From the National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.L.v.d.A., J.M.A.B.); Julius Center for Health Sciences and Primary Care (D.L.v.d.A., M.M.R., D.E.G., Y.T.v.d.S.) and Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation (J.J.M.M.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif (J.W.); Department of Clinical
| | - Jill Waalen
- From the National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.L.v.d.A., J.M.A.B.); Julius Center for Health Sciences and Primary Care (D.L.v.d.A., M.M.R., D.E.G., Y.T.v.d.S.) and Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation (J.J.M.M.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif (J.W.); Department of Clinical
| | - Christina Ellervik
- From the National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.L.v.d.A., J.M.A.B.); Julius Center for Health Sciences and Primary Care (D.L.v.d.A., M.M.R., D.E.G., Y.T.v.d.S.) and Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation (J.J.M.M.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif (J.W.); Department of Clinical
| | - B�rge G. Nordestgaard
- From the National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.L.v.d.A., J.M.A.B.); Julius Center for Health Sciences and Primary Care (D.L.v.d.A., M.M.R., D.E.G., Y.T.v.d.S.) and Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation (J.J.M.M.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif (J.W.); Department of Clinical
| | - John K. Olynyk
- From the National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.L.v.d.A., J.M.A.B.); Julius Center for Health Sciences and Primary Care (D.L.v.d.A., M.M.R., D.E.G., Y.T.v.d.S.) and Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation (J.J.M.M.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif (J.W.); Department of Clinical
| | - Peter R. Mills
- From the National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.L.v.d.A., J.M.A.B.); Julius Center for Health Sciences and Primary Care (D.L.v.d.A., M.M.R., D.E.G., Y.T.v.d.S.) and Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation (J.J.M.M.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif (J.W.); Department of Clinical
| | - James Shepherd
- From the National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.L.v.d.A., J.M.A.B.); Julius Center for Health Sciences and Primary Care (D.L.v.d.A., M.M.R., D.E.G., Y.T.v.d.S.) and Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation (J.J.M.M.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif (J.W.); Department of Clinical
| | - Bernard Grandchamp
- From the National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.L.v.d.A., J.M.A.B.); Julius Center for Health Sciences and Primary Care (D.L.v.d.A., M.M.R., D.E.G., Y.T.v.d.S.) and Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation (J.J.M.M.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif (J.W.); Department of Clinical
| | - Jolanda M.A. Boer
- From the National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.L.v.d.A., J.M.A.B.); Julius Center for Health Sciences and Primary Care (D.L.v.d.A., M.M.R., D.E.G., Y.T.v.d.S.) and Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation (J.J.M.M.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif (J.W.); Department of Clinical
| | - Calogero Caruso
- From the National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.L.v.d.A., J.M.A.B.); Julius Center for Health Sciences and Primary Care (D.L.v.d.A., M.M.R., D.E.G., Y.T.v.d.S.) and Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation (J.J.M.M.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif (J.W.); Department of Clinical
| | - Marcello Arca
- From the National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.L.v.d.A., J.M.A.B.); Julius Center for Health Sciences and Primary Care (D.L.v.d.A., M.M.R., D.E.G., Y.T.v.d.S.) and Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation (J.J.M.M.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif (J.W.); Department of Clinical
| | - Beat J. Meyer
- From the National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.L.v.d.A., J.M.A.B.); Julius Center for Health Sciences and Primary Care (D.L.v.d.A., M.M.R., D.E.G., Y.T.v.d.S.) and Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation (J.J.M.M.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif (J.W.); Department of Clinical
| | - Yvonne T. van der Schouw
- From the National Institute for Public Health and the Environment, Bilthoven, the Netherlands (D.L.v.d.A., J.M.A.B.); Julius Center for Health Sciences and Primary Care (D.L.v.d.A., M.M.R., D.E.G., Y.T.v.d.S.) and Eijkman Winkler Institute for Microbiology, Infectious Diseases, and Inflammation (J.J.M.M.), University Medical Center Utrecht, Utrecht, the Netherlands; Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, Calif (J.W.); Department of Clinical
| |
Collapse
|
18
|
Dunn T, Blankenship D, Beal N, Allen R, Schechter E, Moore W, Perveen G, Eichner J. HFE mutations in heart disease. Heart Vessels 2008; 23:348-55. [DOI: 10.1007/s00380-008-1047-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/09/2007] [Accepted: 02/05/2008] [Indexed: 11/30/2022]
|
19
|
Zhang L, Rao F, Zhang K, Khandrika S, Das M, Vaingankar SM, Bao X, Rana BK, Smith DW, Wessel J, Salem RM, Rodriguez-Flores JL, Mahata SK, Schork NJ, Ziegler MG, O’Connor DT. Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk. J Clin Invest 2007; 117:2658-71. [PMID: 17717598 PMCID: PMC1950457 DOI: 10.1172/jci31093] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2006] [Accepted: 05/18/2007] [Indexed: 11/17/2022] Open
Abstract
GTP cyclohydrolase 1 (GCH1) is rate limiting in the provision of the cofactor tetrahydrobiopterin for biosynthesis of catecholamines and NO. We asked whether common genetic variation at GCH1 alters transmitter synthesis and predisposes to disease. Here we undertook a systematic search for polymorphisms in GCH1, then tested variants' contributions to NO and catecholamine release as well as autonomic function in twin pairs. Renal NO and neopterin excretions were significantly heritable, as were baroreceptor coupling (heart rate response to BP fluctuation) and pulse interval (1/heart rate). Common GCH1 variant C+243T in the 3'-untranslated region (3'-UTRs) predicted NO excretion, as well as autonomic traits: baroreceptor coupling, maximum pulse interval, and pulse interval variability, though not catecholamine secretion. In individuals with the most extreme BP values in the population, C+243T affected both diastolic and systolic BP, principally in females. In functional studies, C+243T decreased reporter expression in transfected 3'-UTRs plasmids. We conclude that human NO secretion traits are heritable, displaying joint genetic determination with autonomic activity by functional polymorphism at GCH1. Our results document novel pathophysiological links between a key biosynthetic locus and NO metabolism and suggest new strategies for approaching the mechanism, diagnosis, and treatment of risk predictors for cardiovascular diseases such as hypertension.
Collapse
Affiliation(s)
- Lian Zhang
- Department of Medicine,
Department of Psychiatry, and
Department of Biology, UCSD School of Medicine, San Diego, California, USA.
VA San Diego Healthcare System, San Diego, California, USA.
Center for Human Genetics and Genomics and
Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA
| | - Fangwen Rao
- Department of Medicine,
Department of Psychiatry, and
Department of Biology, UCSD School of Medicine, San Diego, California, USA.
VA San Diego Healthcare System, San Diego, California, USA.
Center for Human Genetics and Genomics and
Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA
| | - Kuixing Zhang
- Department of Medicine,
Department of Psychiatry, and
Department of Biology, UCSD School of Medicine, San Diego, California, USA.
VA San Diego Healthcare System, San Diego, California, USA.
Center for Human Genetics and Genomics and
Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA
| | - Srikrishna Khandrika
- Department of Medicine,
Department of Psychiatry, and
Department of Biology, UCSD School of Medicine, San Diego, California, USA.
VA San Diego Healthcare System, San Diego, California, USA.
Center for Human Genetics and Genomics and
Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA
| | - Madhusudan Das
- Department of Medicine,
Department of Psychiatry, and
Department of Biology, UCSD School of Medicine, San Diego, California, USA.
VA San Diego Healthcare System, San Diego, California, USA.
Center for Human Genetics and Genomics and
Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA
| | - Sucheta M. Vaingankar
- Department of Medicine,
Department of Psychiatry, and
Department of Biology, UCSD School of Medicine, San Diego, California, USA.
VA San Diego Healthcare System, San Diego, California, USA.
Center for Human Genetics and Genomics and
Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA
| | - Xuping Bao
- Department of Medicine,
Department of Psychiatry, and
Department of Biology, UCSD School of Medicine, San Diego, California, USA.
VA San Diego Healthcare System, San Diego, California, USA.
Center for Human Genetics and Genomics and
Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA
| | - Brinda K. Rana
- Department of Medicine,
Department of Psychiatry, and
Department of Biology, UCSD School of Medicine, San Diego, California, USA.
VA San Diego Healthcare System, San Diego, California, USA.
Center for Human Genetics and Genomics and
Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA
| | - Douglas W. Smith
- Department of Medicine,
Department of Psychiatry, and
Department of Biology, UCSD School of Medicine, San Diego, California, USA.
VA San Diego Healthcare System, San Diego, California, USA.
Center for Human Genetics and Genomics and
Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA
| | - Jennifer Wessel
- Department of Medicine,
Department of Psychiatry, and
Department of Biology, UCSD School of Medicine, San Diego, California, USA.
VA San Diego Healthcare System, San Diego, California, USA.
Center for Human Genetics and Genomics and
Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA
| | - Rany M. Salem
- Department of Medicine,
Department of Psychiatry, and
Department of Biology, UCSD School of Medicine, San Diego, California, USA.
VA San Diego Healthcare System, San Diego, California, USA.
Center for Human Genetics and Genomics and
Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA
| | - Juan L. Rodriguez-Flores
- Department of Medicine,
Department of Psychiatry, and
Department of Biology, UCSD School of Medicine, San Diego, California, USA.
VA San Diego Healthcare System, San Diego, California, USA.
Center for Human Genetics and Genomics and
Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA
| | - Sushil K. Mahata
- Department of Medicine,
Department of Psychiatry, and
Department of Biology, UCSD School of Medicine, San Diego, California, USA.
VA San Diego Healthcare System, San Diego, California, USA.
Center for Human Genetics and Genomics and
Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA
| | - Nicholas J. Schork
- Department of Medicine,
Department of Psychiatry, and
Department of Biology, UCSD School of Medicine, San Diego, California, USA.
VA San Diego Healthcare System, San Diego, California, USA.
Center for Human Genetics and Genomics and
Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA
| | - Michael G. Ziegler
- Department of Medicine,
Department of Psychiatry, and
Department of Biology, UCSD School of Medicine, San Diego, California, USA.
VA San Diego Healthcare System, San Diego, California, USA.
Center for Human Genetics and Genomics and
Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA
| | - Daniel T. O’Connor
- Department of Medicine,
Department of Psychiatry, and
Department of Biology, UCSD School of Medicine, San Diego, California, USA.
VA San Diego Healthcare System, San Diego, California, USA.
Center for Human Genetics and Genomics and
Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA
| |
Collapse
|
20
|
Rao F, Wen G, Gayen JR, Das M, Vaingankar SM, Rana BK, Mahata M, Kennedy BP, Salem RM, Stridsberg M, Abel K, Smith DW, Eskin E, Schork NJ, Hamilton BA, Ziegler MG, Mahata SK, O'Connor DT. Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 2007; 115:2271-81. [PMID: 17438154 DOI: 10.1161/circulationaha.106.628859] [Citation(s) in RCA: 93] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
BACKGROUND Chromogranin A, coreleased with catecholamines by exocytosis, is cleaved to the catecholamine release-inhibitory fragment catestatin. We identified a natural nonsynonymous variant of catestatin, Gly364Ser, that alters human autonomic function and blood pressure. METHODS AND RESULTS Gly364Ser heterozygotes and controls underwent physiological and biochemical phenotyping, including catecholamine production, chromogranin A precursor, and its catestatin product. Case-control studies replicated effects of the gene on blood pressure in the population. Gly364Ser displayed diminished inhibition of catecholamine secretion from cultured neurons. Gly/Ser heterozygotes displayed increased baroreceptor slope during upward deflections (by approximately 47%) and downward deflections (by approximately 44%), increased cardiac parasympathetic index (by approximately 2.4-fold), and decreased cardiac sympathetic index (by approximately 26%). Renal norepinephrine excretion was diminished by approximately 26% and epinephrine excretion by approximately 34% in Gly/Ser heterozygotes. The coalescent dated emergence of the variant to approximately 70,000 years ago. Gly364Ser was in linkage disequilibrium with 1 major Chromogranin A promoter haplotype, although promoter haplotypes did not predict autonomic phenotypes. The 364Ser variant was associated with lower diastolic blood pressure in 2 independent/confirmatory groups of patients with hypertension; genotype groups differed by approximately 5 to 6 mm Hg, and the polymorphism accounted for approximately 1.8% of population diastolic blood pressure variance, although a significant gene-by-sex interaction existed, with an enhanced effect in men. CONCLUSIONS The catestatin Gly364Ser variant causes profound changes in human autonomic activity, both parasympathetic and sympathetic, and seems to reduce risk of developing hypertension, especially in men. A model for catestatin action in the baroreceptor center of the nucleus of the tractus solitarius accounts for these actions.
Collapse
Affiliation(s)
- Fangwen Rao
- Department of Medicine, University of California at San Diego, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Rana BK, Insel PA, Payne SH, Abel K, Beutler E, Ziegler MG, Schork NJ, O'Connor DT. Population-based sample reveals gene-gender interactions in blood pressure in White Americans. Hypertension 2006; 49:96-106. [PMID: 17159089 DOI: 10.1161/01.hyp.0000252029.35106.67] [Citation(s) in RCA: 100] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The influence of genetic contributors, such as common single nucleotide polymorphisms, on blood pressure and essential hypertension may vary with the gender. We used the power of a large, community-based sample to probe whether gender interacts with genes in contributing to extremes of blood pressure in 611 male and 656 female age-matched white Americans within the top and bottom 5th percentiles of blood pressure among >53 000 people in a health maintenance program. This approach has >90% statistical power to detect genes contributing as little as 3% to trait (blood pressure) variation. We scored approximately 60 000 genotypes in the subjects: 48 single nucleotide polymorphisms at 33 autosomal and 2 X-linked genes in adrenergic and renal pathways that regulate blood pressure. Six individual variants significantly affected blood pressure and demonstrated gene-by-gender interaction, yielding different effects of the single nucleotide polymorphism on blood pressure in males and females. In females, polymorphisms at beta(1)-adrenergic receptor and alpha(2A)-adrenergic receptor contributed to blood pressure, whereas in men, polymorphisms at beta(2)-adrenergic receptor and angiotensinogen were associated. An alpha(2A)-adrenergic receptor haplotype influenced blood pressure in women, whereas 2 angiotensinogen haplotypes were associated in men. We also detected gene-by-gene, gender-specific interactions (epistasis) in pathophysiological pathways. This study reveals gender-specific effects of single nucleotide polymorphisms, haplotypes, and gene-by-gene interactions that determine blood pressure in white Americans. Such genetic variants may define genetically and etiologically distinct subgroups of men and women with essential hypertension and may have implications for rational treatment selection.
Collapse
Affiliation(s)
- Brinda K Rana
- Department of Psychiatry, University of California at San Diego, La Jolla, CA 92093, USA
| | | | | | | | | | | | | | | |
Collapse
|
22
|
van der A DL, Peeters PHM, Grobbee DE, Roest M, Marx JJM, Voorbij HM, van der Schouw YT. HFE mutations and risk of coronary heart disease in middle-aged women. Eur J Clin Invest 2006; 36:682-90. [PMID: 16968463 DOI: 10.1111/j.1365-2362.2006.01711.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Although heterozygosity for the C282Y mutation in the HFE gene has been associated with an increased risk of cardiovascular events, epidemiological studies remain inconclusive. The aim of the present study was to obtain further evidence as to whether HFE mutations are associated with risk of coronary heart disease (CHD) in middle-aged women. We used data of a cohort of 15 236 Dutch middle-aged women to investigate whether C282Y carriers and H63D carriers are at increased risk of coronary heart disease compared with non-carriers. MATERIALS AND METHODS Women were included in the study between 1993 and 1997 and were followed until 1 January 2000 for cardiovascular events. HFE genotyping was performed on all 211 coronary heart disease cases and a randomly selected sample from the baseline cohort (n = 1526). A weighted Cox proportional hazards model was used to estimate crude, age-adjusted and multivariate adjusted hazard ratios for C282Y and H63D carriership in relation to coronary heart disease. RESULTS Compared with non-carriers, those that carried the C282Y allele were not at increased risk for CHD (HR = 1.25, 95% CI = 0.74-2.09). Neither did we find an association between the H63D mutation and CHD risk (HR = 0.73, 95% CI = 0.43-1.24). CONCLUSIONS Our results are in accordance with similar studies to date, for which we present a meta-analysis. HFE mutations appear not to affect the risk of coronary heart disease.
Collapse
|
23
|
Waalen J, Beutler E. Beware of multiple comparisons: a study of symptoms associated with mutations of the HFE hemochromatosis gene. Clin Chim Acta 2005; 361:128-34. [PMID: 15993396 DOI: 10.1016/j.cccn.2005.05.017] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2005] [Accepted: 05/07/2005] [Indexed: 10/25/2022]
Abstract
BACKGROUND Studies involving a large number of comparisons have a high likelihood of finding statistically significant associations by chance alone (Type 1 error). Genetic association studies are particularly prone to this pitfall. We tested the effect of multiple comparisons in a study of symptoms among subjects genotyped for mutations of the HFE hemochromatosis gene. METHODS Two randomly selected groups were created from a dataset of 30,917 white adult subjects genotyped for the C282Y and H63D mutations of the HFE gene. Frequency of symptoms among subjects with different HFE genotypes was compared to sex-matched wild type controls in Random Group 1 (hypothesis generation). Statistically significant associations (p<0.05 by chi2) were then tested in Random Group 2 (hypothesis testing). RESULTS A total of 101/1765 associations in men and 116/2015 associations in women were statistically significant in Random Group 1. Of these, 12 associations in men and 13 associations in women were also statistically significant in Random Group 2, 11 of which were specific to hemochromatosis. None of the remaining 14 associations (6 in men and 8 in women) involved symptoms with a biologically plausible relationship to hemochromatosis or iron overload. CONCLUSIONS Genetic association studies should be scrutinized for the possibility of Type 1 error.
Collapse
Affiliation(s)
- Jill Waalen
- Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
| | | |
Collapse
|
24
|
Ellervik C, Tybjaerg-Hansen A, Grande P, Appleyard M, Nordestgaard BG. Hereditary Hemochromatosis and Risk of Ischemic Heart Disease. Circulation 2005; 112:185-93. [PMID: 15998685 DOI: 10.1161/circulationaha.104.496075] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
We tested the hypothesis that the hereditary hemochromatosis genotypes C282Y/C282Y, C282Y/H63D, or C282Y/wild-type are risk factors for ischemic heart disease (IHD) and myocardial infarction (MI).
Methods and Results—
We performed a prospective study of 9178 individuals from the Danish general population followed up for 24 years, during which 1035 and 511 developed IHD and MI, respectively, and a case-control study of 2441 and 1113 IHD and MI cases versus 8080 controls. C282Y/C282Y, C282Y/H63D, and C282Y/wild-type versus wild-type/wild-type individuals were not associated with increased risk of IHD or MI in prospective studies, overall or stratified by gender. We had 90% power to detect a hazard ratio for IHD of 3.4 for C282Y/C282Y, 1.9 for C282Y/H63D, and 1.3 for C282Y/wild-type versus wild-type/wild-type. Furthermore, these genotypes were not associated with increased risk of IHD or MI in case-control studies, overall or stratified by gender. We had 90% power to detect an odds ratio for IHD of 3.6 for C282Y/C282Y, 1.8 for C282Y/H63D, and 1.3 for C282Y/wild-type versus wild-type/wild-type.
Conclusions—
In these studies, hereditary hemochromatosis C282Y/C282Y, C282Y/H63D, and C282Y/wild-type genotypes were not associated with IHD or MI; however, the study lacked the power to exclude the possibility that C282Y/C282Y and C282Y/H63D individuals have a modestly increased risk of IHD or MI.
Collapse
Affiliation(s)
- Christina Ellervik
- Department of Clinical Biochemistry, Herlev University Hospital, Herlev, Denmark
| | | | | | | | | |
Collapse
|
25
|
Goland S, Beilinson N, Kaftouri A, Shimoni S, Caspi A, Malnick SDH. Hemochromatosis mutations are not linked to dilated cardiomyopathy in Israeli patients. Eur J Heart Fail 2004; 6:547-50. [PMID: 15302000 DOI: 10.1016/j.ejheart.2003.11.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/08/2003] [Revised: 09/17/2003] [Accepted: 11/13/2003] [Indexed: 11/26/2022] Open
Abstract
AIMS Hemochromatosis is a condition in which iron loading impairs the function of many organs, including the heart. Congestive heart failure with left ventricular dilatation is commonly found in patients with hemochromatosis. Two missense mutations (C282Y and H63D) have been shown to be responsible for the majority of cases of hemochromatosis. METHODS AND RESULTS We examined 156 patients with congestive heart failure due to dilated cardiomyopathy. Details were recorded of clinical and echocardiographic parameters. DNA was extracted from peripheral blood and checked for the presence of the C282Y and H63D mutations by a commercially available single nucleotide primer extension assay. A control group of 98 healthy blood donors was also checked for the presence of these mutations. Of the 157 patients, 42 (26.75%) had at least one mutation. Five (3.65%) were homozygotic for the H63D mutation and 37 (23.6%) were heterozygotic for the H63D mutation. The C282Y mutation was not present. In a control population of 98 healthy blood donors, 27 (27.6%) were heterozygous for the H63D population and none had the C282Y mutation (no significant difference between the patients with cardiomyopathy and the healthy blood donors, chi(2) test 0.754). There was a non-significant trend to a difference in the prevalence of homozygotic H63D between the cardiomyopathy patients and the healthy blood donors (3.18% vs. 0%, P=0.076, chi(2) test). There was no statistically significant difference between the cardiomyopathy patients with and without the mutations in terms of age, gender, hemoglobin, iron, transferrin, ferritin, presence of diabetes mellitus, hypertension and previous coronary artery bypass grafting. CONCLUSION In our population of patients with dilated cardiomyopathy, there was no evidence for hemochromatosis being an important etiology.
Collapse
Affiliation(s)
- Sorel Goland
- Heart Institute, Kaplan Medical Center, Rehovot 76100, Israel.
| | | | | | | | | | | |
Collapse
|
26
|
Hunt JR, Zeng H. Iron absorption by heterozygous carriers of the HFE C282Y mutation associated with hemochromatosis. Am J Clin Nutr 2004; 80:924-31. [PMID: 15447900 DOI: 10.1093/ajcn/80.4.924] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND Research conducted before genotyping was possible suggested that subjects heterozygous for the genetic mutation associated with hemochromatosis absorbed nonheme iron more efficiently than did control subjects when tested with a fortified meal. Heme-iron absorption in these subjects has not been reported. OBJECTIVE We compared the absorption of heme and nonheme iron from minimally or highly fortified test meals between HFE C282Y-heterozygous and wild-type control subjects. DESIGN After prospective genotyping of 256 healthy volunteers, 11 C282Y-heterozygous and 12 wild-type control subjects were recruited, and their iron absorption was compared by using a hamburger test meal with or without added iron and ascorbic acid. After retrospective genotyping of 103 participants in previous iron-absorption studies, 5 C282Y-heterozygous subjects were compared with 72 wild-type control subjects. RESULTS HFE C282Y-heterozygous subjects did not differ significantly from wild-type control subjects in their absorption of either heme or nonheme iron from minimally or highly fortified test meals. No differences were detected in blood indexes of iron status (including serum ferritin, transferrin saturation, and non-transferrin-bound iron) or in blood lipids or transaminases, but heterozygotes had significantly greater, although normal, fasting glucose concentrations than did wild-type control subjects. Compound heterozygotes (those who had both HFE C282Y and H63D mutations) absorbed more nonheme (but not heme) iron from meals with high (but not low) iron bioavailability. CONCLUSIONS HFE C282Y-heterozygous subjects did not absorb dietary iron more efficiently, even when foods were highly fortified with iron from ferrous sulfate and ascorbic acid, than did control subjects. Iron fortification of foods should not pose an additional health risk to HFE C282Y heterozygotes.
Collapse
Affiliation(s)
- Janet R Hunt
- US Department of Agriculture, Agricultural Research Service, Grand Forks Human Nutrition Research Center, Grand Forks, ND, USA.
| | | |
Collapse
|
27
|
McCarthy JJ, Parker A, Salem R, Moliterno DJ, Wang Q, Plow EF, Rao S, Shen G, Rogers WJ, Newby LK, Cannata R, Glatt K, Topol EJ. Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes. J Med Genet 2004; 41:334-41. [PMID: 15121769 PMCID: PMC1579684 DOI: 10.1136/jmg.2003.016584] [Citation(s) in RCA: 99] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND to date, only three groups have reported data from large scale genetic association studies of coronary heart disease using a case control design. METHODS AND RESULTS to extend our initial report of 62 genes, we present data for 210 polymorphisms in 111 candidate genes genotyped in 352 white subjects with familial, premature coronary heart disease (onset age for men, 45; for women, 50) and a random sample of 418 population based whites. Multivariate logistic regression analysis was used to compare the distributions of genotypes between cases and the comparison group while controlling for age, sex, body mass, diabetes, and hypertension. Significant associations were found with polymorphisms in thrombospondin-4 (THBS4), thrombospondin-2 (THBS2) and plasminogen activator inhibitor-2 (PAI2), the strongest being with the A387P variant in THBS4 (p = 0.002). The THBS2 and THBS4 associations have since been replicated. We evaluated polymorphisms in 40 genes previously associated with coronary heart disease and found significant (p<0.05) associations with 10: ACE, APOE, F7, FGB, GP1BA, IL1RN, LRP1, MTHFR, SELP, and THPO. For five of these genes, the polymorphism associated in our study was different from that previously reported, suggesting linkage disequilibrium as an explanation for failure to replicate associations consistently across studies. We found strong linkage disequilibrium between polymorphisms within and between genes, especially on chromosome 1q22-q25, a region containing several candidate genes. CONCLUSIONS despite known caveats of genetic association studies, they can be an effective means of hypothesis generation and complement classic linkage studies for understanding the genetic basis of coronary heart disease.
Collapse
Affiliation(s)
- J J McCarthy
- San Diego State University, San Diego, CA 92182, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Candore G, Balistreri CR, Lio D, Mantovani V, Colonna-Romano G, Chiappelli M, Tampieri C, Licastro F, Branzi A, Averna M, Caruso M, Hoffmann E, Caruso C. Association between HFE mutations and acute myocardial infarction: a study in patients from Northern and Southern Italy. Blood Cells Mol Dis 2003; 31:57-62. [PMID: 12850485 DOI: 10.1016/s1079-9796(03)00065-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
There is interest in the role of iron in age-related diseases such as atherosclerosis. Tissue iron deposition could be harmful, because Fe(2+) can react with H(2)O(2) to form OH(-) radicals and Fe(2+) can react with O(2) to form reactive oxygen species. Free radicals react with cell membranes and cell organelles and could lead to the development of atherosclerosis by initiating lipid peroxidation. Hereditary hemochromatosis provides an opportunity for studying the effects of iron on cardiovascular disease. Some studies have shown that individuals who carried HFE mutations may be at greater risk of developing coronary heart disease than those without the mutations. In contrast, a large number of studies have reported no association between HFE mutations and coronary heart disease. These studies have possible confounding factors, such as the homogeneity of the population in term of geographical origin among others. We studied the relation between HFE mutations and acute myocardial infarction in two case-control studies involving two sets of subjects representing different age groups from different geographic regions in Italy. The first one was composed of 172 older patients (139 males and 33 females; mean age 67) and 207 healthy controls (91 males and 116 females; mean age 46) from Emilia-Romagna. The second one was composed of younger 77 patients (75 males and 2 females; mean age 41) and 172 healthy controls (75 males and 97 females, mean age: 38) from Sicily. All patients were genotyped for ApoE alleles, since the ApoE- epsilon 4 allele is considered a risk factor for cardiovascular diseases and can interfere with other genetic and environmental factors by modifying susceptibility to this disease. DNA typing for C282Y and H63D HFE alleles was performed also. There were no significant differences in frequencies of the different HFE alleles between acute myocardial infarction patients and controls in cohorts of both old and young patients. Also taking into account the presence or absence of the ApoE- epsilon 4 allele, no significant differences in H63D allele frequencies were observed. Thus, our study, performed in two samples of genetically homogeneous patients and controls, does not support the suggestion that HFE mutations may be associated with acute myocardial infarction in susceptible individuals.
Collapse
Affiliation(s)
- Giuseppina Candore
- Gruppo di studio sull'immunosenescenza, Dipartimento di Biopatologia e Metodologie Biomediche, Università di Palermo, Palermo, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
AbstractIn the past seven years numerous genes that influence iron homeostasis have been discovered. Dr. Beutler provides a brief overview of these genes, genes that encode HFE, DMT-1, ferroportin, transferrin receptor 2, hephaestin, and hepcidin to lay the groundwork for a discussion of the various clinical forms of iron storage disease and how they differ from one another.In Section I, Dr. Beutler also discusses the types of hemochromatosis that exist as acquired and as hereditary forms. Acquired hemochromatosis occurs in patients with marrow failure, particularly when there is active ineffective erythropoiesis. Hereditary hemochromatosis is most commonly due to mutations in the HLA-linked HFE gene, and hemochromatosis clinically indistinguishable from HFE hemochromatosis is the consequence of mutations in three transferrin receptor-2 gene. A more severe, juvenile form of iron storage disease results from mutations of the gene encoding hepcidin or of a not-yet-identified gene on chromosome 1q. Autosomal dominant iron storage disease is a consequence of ferroportin mutations, and a polymorphism in the ferroportin gene appears to be involved in the African iron overload syndrome.Evidence regarding the biochemical and clinical penetrance of hemochromatosis due to mutations of the HFE gene is rapidly accumulating. These studies, emanating from several centers in Europe and the United States, all agree that the penetrance of hemochromatosis is much lower than had previously been thought. Probably only 1% of homozygotes develop clinical findings. The implications of these new findings for the management of hemochromatosis will be discussed.In Section II, Dr. Victor Hoffbrand discusses the management of iron storage disease by chelation therapy, treatment that is usually reserved for patients with secondary hemochromatosis such as occurs in the thalassemias and in patients with transfusion requirements due to myelodysplasia and other marrow failure states. Tissue iron can be estimated by determining serum ferritin levels, measuring liver iron, and by measuring cardiac iron using the MRI-T2* technique. The standard form of chelation therapy is the slow intravenous or subcutaneous infusion of desferoxamine. An orally active bidentate iron chelator, deferiprone, is now licensed in 25 countries for treatment of patients with thalassemia major. Possibly because of the ability of this compound to cross membranes, it appears to have superior cardioprotective properties. Agranulocytosis is the most serious complication of deferiprone therapy and occurs in about 1% of treated patients. Deferiprone and desferoxamine can be given together or on alternating schedules. A new orally active chelating agent ICL 670 seems promising in early clinical studies.In Section III, Dr. James Cook discusses the most common disorder of iron homeostasis, iron deficiency. He will compare some of the standard methods for identifying iron deficiency, the hemoglobin level, transferrin saturation, and mean corpuscular hemoglobin and compare these with some of the newer methods that have been introduced, specifically the percentage of hypochromic erythrocytes and reticulocyte hemoglobin content. The measurement of storage iron is achieved by measuring serum ferritin levels. The soluble transferrin receptor is a truncated form of the cellular transferrin receptor and the possible value of this measurement in the diagnosis of iron deficiency will be discussed. Until recently iron dextran was the only parental iron preparation available in the US. Sodium ferric gluconate, which has been used extensively in Europe for many years, is now available in the United States. It seems to have a distinct advantage over iron dextran in that anaphylactic reactions are much less common with the latter preparation.
Collapse
|